查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
亞太地區細胞與基因治療製造品質控制市場：分析與預測（2023-2033）
市場調查報告書
商品編碼
1416208

亞太地區細胞與基因治療製造品質控制市場：分析與預測（2023-2033）

Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 101 Pages | 商品交期: 1-5個工作天內

價格
主要市場統計數據
預測期 2023-2033
2023年評估 4.263 億美元
2033年預測 22.336 億美元
複合年成長率 18.01%

2023 年，亞太地區細胞和基因治療製造品質控制市場規模達 4.263 億美元。

預計到 2033 年，市場規模將達到 22.336 億美元，2023-2033 年預測期間複合年成長率為 18.01%。由於核准治療方法的增加以及基礎設施擴張的需求，細胞和基因療法製造 QC (QC) 市場預計將成長。此外，細胞和基因療法針對的多種病理需要廣泛的製造和品質控制流程，從而促進市場成長。

亞太地區的細胞和基因治療製造品質控制 (QC) 市場正在經歷顯著成長。這一市場擴張背後有幾個因素，包括先進療法的採用增加、生物技術和製藥行業投資的增加以及熟練勞動力的存在。此外，該地區慢性病盛行率的不斷上升正在加速對創新細胞和基因療法的需求，從而需要嚴格的品質控制措施。新興國家正積極參與研發活動並促進與生技公司的合作。因此，亞太地區的細胞和基因治療製造品質控制市場預計在未來幾年將顯著成長，從而促進該地區醫療保健解決方案的發展。

本報告探討了亞太地區細胞和基因治療製造品質控制市場，提供了市場概述、按治療類型、產品、工藝、應用、技術、國家和進入市場的公司分類的趨勢。我們提供簡介等。

目錄

執行摘要

第1章 市場

  • 產品定義
  • 調查方法
  • 市場概況
    • 市集情境
    • 市場足跡和成長潛力
    • 未來性
    • COVID-19 對市場的影響

第2章細胞/基因治療製造QC市場：產業分析

  • 法律規範
    • 食品藥物管理局(FDA) 的化學、製造和控制 (CMC) 要求
    • 歐洲藥品管理局 (EMA) 的細胞和基因治療產品品質方面
    • 現行良好生產規範 (CGMP) 法規
    • 法律規範：細胞和基因治療製造品質控制市場

第3章 細胞/基因治療製造QC市場（按地區）

  • 概述
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 印度
    • 其他地區

第4章 公司簡介

Product Code: BHP1817SS

“The Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Expected to Reach $2,233.6 Million by 2033.”

Introduction to Asia-Pacific Cell and Gene Therapy Manufacturing QC Market

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$426.3 Million
2033 Forecast$2,233.6 Million
CAGR18.01%

The Asia-Pacific cell and gene therapy manufacturing QC market was valued at $426.3 million in 2023 and is expected to reach $2,233.6 million by 2033, growing at a CAGR of 18.01% during the forecast period 2023-2033. The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The Asia-Pacific (APAC) region is witnessing significant growth in the cell and gene therapy manufacturing quality control (QC) market. This expansion is driven by several factors, including the rising adoption of advanced therapies, increasing investments in biotechnology and pharmaceutical sectors, and the presence of a skilled workforce. Moreover, the growing prevalence of chronic diseases in the region has accelerated the demand for innovative cell and gene therapies, necessitating stringent QC measures. APAC countries are actively involved in research and development activities, fostering collaborations with biotech companies. As a result, the APAC cell and gene therapy manufacturing QC market is poised for substantial growth in the coming years, contributing to the advancement of healthcare solutions in the region.

Market Segmentation

Segmentation 1: by Therapy Type

  • Cell Therapy
  • Gene Therapy

Segmentation 2: by Offering

  • Products
  • Services

Segmentation 3: by Process

  • Raw Material Preparation
  • Upstream Processing
  • Downstream Processing
  • Packaging

Segmentation 4: by Application

  • Safety Testing
  • Potency Testing
  • Identity Testing
  • Stability and Genetic Fidelity Testing
  • Others

Segmentation 5: by Technology

  • Polymerase Chain Reaction (PCR)
  • Flow Cytometry
  • Limulus Amebocyte Lysate (LAL)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chromatography
  • Mass Spectrometry
  • Western Blotting
  • Next-Generation Sequencing (NGS)
  • Electrophoresis
  • Other Technologies

Segmentation 6: by Country

  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Rest-of-Asia-Pacific and Japan

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current APAC cell and gene therapy manufacturing QC market.

Competitive Strategy: Key players in the APAC cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Markets

  • 1.1. Product Definition
    • 1.1.1. Product Definition
    • 1.1.2. Inclusion and Exclusion Criteria
  • 1.2. Market Scope
    • 1.2.1. Key Questions Answered in the Report
  • 1.3. Research Methodology
    • 1.3.1. Cell and Gene Therapy Manufacturing QC Market
    • 1.3.2. Data Sources
      • 1.3.2.1. Primary Data Sources
      • 1.3.2.2. Secondary Data Sources
    • 1.3.3. Market Estimation Model
    • 1.3.4. Criteria for Company Profiling
  • 1.4. Market Overview
    • 1.4.1. Market Scenario
      • 1.4.1.1. Realistic Growth Scenario
      • 1.4.1.2. Optimistic Scenario
      • 1.4.1.3. Pessimistic Scenario
    • 1.4.2. Market Footprint and Growth Potential
    • 1.4.3. Future Potential
    • 1.4.4. COVID-19 Impact on Market
      • 1.4.4.1. Impact on Research and Clinical Operations
      • 1.4.4.2. COVID-19 Impact: Current Scenario of the Market
      • 1.4.4.3. Pre- and Post-COVID-19 Impact Assessment
        • 1.4.4.3.1. Pre-COVID-19 Phase
        • 1.4.4.3.2. Post-COVID-19 Phase

2. Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

  • 2.1. Regulatory Framework
    • 2.1.1. Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
      • 2.1.1.1. Product Testing
      • 2.1.1.2. Microbial Testing
      • 2.1.1.3. Identity
      • 2.1.1.4. Purity
      • 2.1.1.5. Potency
      • 2.1.1.6. Viability
      • 2.1.1.7. Cell Number or Dose
    • 2.1.2. Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
      • 2.1.2.1. Characterization
      • 2.1.2.2. Identity Testing
      • 2.1.2.3. Purity Testing
    • 2.1.3. Current Good Manufacturing Practice (CGMP) Regulations
    • 2.1.4. Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3. Cell and Gene Therapy Manufacturing QC Market (by Region)

  • 3.1. Overview
  • 3.2. Asia-Pacific
      • 3.2.1.1. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.1.2. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.1.3. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.1.4. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.1.5. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.2. China
      • 3.2.2.1. China Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.2.2. China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.2.3. China Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.2.4. China Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.2.5. China Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.3. Japan
      • 3.2.3.1. Japan Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.3.2. Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.3.3. Japan Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.3.4. Japan Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.3.5. Japan Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.4. South Korea
      • 3.2.4.1. South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.4.2. South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.4.3. South Korea Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.4.4. South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.4.5. South Korea Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.5. Australia
      • 3.2.5.1. Australia Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.5.2. Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.5.3. Australia Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.5.4. Australia Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.5.5. Australia Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.6. India
      • 3.2.6.1. India Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.6.2. India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.6.3. India Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.6.4. India Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.6.5. India Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.7. Rest-of-Asia-Pacific
      • 3.2.7.1. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.7.2. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.7.3. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.7.4. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.7.5. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)

4. Company Profiles

  • 4.1. Overview
  • 4.2. Manufacturers
    • 4.2.1. WuXi AppTec
      • 4.2.1.1. Company Overview
      • 4.2.1.2. Role of WuXi AppTec in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.1.3. Key Competitors
      • 4.2.1.4. Financials
      • 4.2.1.5. Analyst Perspective

List of Figures

  • Figure 1: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 2: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, Impact Analysis
  • Figure 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), % Share, 2022 and 2033
  • Figure 4: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), % Share, 2022 and 2033
  • Figure 5: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), % Share, 2022 and 2033
  • Figure 6: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), % Share, 2022 and 2033
  • Figure 7: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), % Share, 2022 and 2033
  • Figure 8: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 9: Cell and Gene Therapy Manufacturing QC Market: Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2033
  • Figure 14: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022-2033
  • Figure 15: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022-2033
  • Figure 16: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 17: Impact of COVID-19 on CGT Developmental Activities
  • Figure 18: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 19: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 20: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Country), % Share, 2022-2033
  • Figure 21: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 22: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 23: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 24: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 25: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 26: China Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 27: China Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 28: China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 29: China Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 30: China Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 31: China Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 32: Japan Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 33: Japan Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 34: Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 35: Japan Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 36: Japan Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 37: Japan Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 38: South Korea Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 39: South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 40: South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 41: South Korea Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 42: South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 43: South Korea Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 44: Australia Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 45: Australia Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 46: Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 47: Australia Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 48: Australia Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 49: Australia Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 50: India Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 51: India Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 52: India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 53: India Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 54: India Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 55: India Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 56: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 57: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 58: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 59: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 60: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 61: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 62: Total Number of Companies Profiled
  • Figure 63: WuXi AppTec: Product Portfolio
  • Figure 64: WuXi AppTec: Overall Financials, $Million, 2020-2022
  • Figure 65: WuXi AppTec: Revenue (by Segment), $Million, 2021 and 2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
  • Table 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis
  • Table 4: Approved Cell and Gene Therapies, Japan